“the 48.04 studies, these are Phase IIbs, one in Crohn's disease and other colitis will be reading out sometime middle of this year.”

In context

“im Securities. Vamil Divan: Again, congrats on the quarter and the performance. I just had one pipeline question on the Innovative Medicines I invest on your [indiscernible] therapy for I thought we might see some of the sort stated already this year, [indiscernible] we didn't see that as we were hoping to see the IVD data here year. So I'm just wondering if you could maybe give us an update on when we should expect to see those to readouts? And then just your general level of enthusiasm, I assume really some of those get in-house, had attempt to see how the competitive dynamics are playing out in the immunology space. So I'd love to just kind of get an update tens of your perspective on Ford's potential? John Reed: Yes, John Reed here. Maybe I'll start and then others can supplement. But the 48.04 studies, these are Phase IIbs, one in Crohn's disease and other colitis will be reading out sometime middle of this year. So it's nearing the time when the data made available and then based on that, we'll make decisions about next steps. As you know, in the earlier Phase IIa study, we saw really compelling data there that it looked like this combination of an IL-23 inhibitor together with a TNF inhibitor 2 products that have been in our pipeline but coming together could break through the traditional efficacy ceilings in patients with difficult-to-treat inflammatory vial disease and give perhaps more than half of those patients the chance had sustainable complete remission. So we're excited about this co-antibody therapeutic. It will be the first of many such approaches to trying to address these difficult-to-treat patients down the line. And so we're excited to be in a leadership role there, the first comp”